Related Experiment Video
Updated: Mar 23, 2026

08:39
Quantifying Leukocyte Egress via Lymphatic Vessels from Murine Skin and Tumors
Published on: January 7, 2019
9.3K
CCR7 and IRF4-dependent dendritic cells regulate lymphatic collecting vessel permeability
The Journal of Clinical Investigation
|March 22, 2016
Summary
The study reveals that the CCR7 molecule controls lymphatic vessel permeability and fibrosis. Interferon regulatory factor 4-positive dendritic cells (IRF4+ DCs) are key players in this process, impacting immune cell flow to lymph nodes.
Area of Science:
- Immunology
- Vascular Biology
- Cell Biology
Background:
- Lymphatic collecting vessels are crucial for immune surveillance, directing lymph and immune cells to lymph nodes (LNs).
- Previous infections can cause lymphatic hyperpermeability, impairing immune cell transport and antigen presentation.
- The molecular mechanisms regulating lymphatic vessel permeability remain largely unknown.
Purpose of the Study:
- To investigate the molecular signals controlling lymphatic collecting vessel permeability.
- To elucidate the role of CCR7 in lymphatic vessel function and fibrosis.
- To identify specific immune cell subsets involved in lymphatic vessel regulation.
Main Methods:
- Analysis of lymphatic collecting vessel permeability and fibrosis in Ccr7-/- mice.
- Investigating the effect of CCR7 reexpression in dendritic cells (DCs).
- Utilizing conditional gene ablation (Cd11c-Cre Irf4fl/fl mice) to study IRF4+ DCs.
Main Results:
- CCR7 deficiency leads to chronic lymphatic collecting vessel hyperpermeability and subsequent fibrosis.
- Reexpression of CCR7 in DCs reverses lymphatic fibrosis.
- Ablation of IRF4+ DCs causes lymphatic collecting vessel hyperpermeability and fibrosis, highlighting their constitutive interaction with lymphatics.
Conclusions:
- CCR7 plays a critical role in maintaining lymphatic collecting vessel integrity and preventing fibrosis.
- IRF4-dependent dendritic cells are key regulators of lymphatic vessel permeability and fibrosis.
- Targeting CCR7 and IRF4+ DCs may offer therapeutic strategies for immune dysfunction associated with lymphatic abnormalities.
More Related Videos
07:14A CFSE-based Assay to Study the Migration of Murine Skin Dendritic Cells into Draining Lymph Nodes During Infection with Mycobacterium bovis Bacille Calmette-Guérin
Published on: October 9, 2016
12.7K
05:59Blocking Lymph Flow by Suturing Afferent Lymphatic Vessels in Mice
Published on: May 14, 2020
7.1K